Advertisement

Annals of Surgical Oncology

, Volume 25, Issue 12, pp 3621–3628 | Cite as

Factors Associated With Host Immune Response and Number of Lymph Nodes: A Large Retrospective Cohort Study

  • Sun-Ju Byeon
  • You Jeong Heo
  • Junhun Cho
  • Ji Yeong An
  • Min Gew Choi
  • Jun Ho Lee
  • Jae Moon Bae
  • Min-Ji Kim
  • Insuk Sohn
  • Sung Kim
  • Kyoung-Mee Kim
  • Tae Sung Sohn
Gastrointestinal Oncology
  • 178 Downloads

Abstract

Background

The host immune response (HIR) against tumor cells is one of the key players in antitumor activities. However, the relationship between HIR and regional lymph nodes (LN) and their impacts on prognosis have not been studied.

Methods

This study analyzed HIR and clinicopathologic factors for 8819 consecutive gastric cancer patients who underwent gastrectomy and D2 LN dissection. The findings confirmed Epstein–Barr virus (EBV) with Epstein–Barr encoding region in situ hybridization, HIR grading (G1, G2, and G3), LN numbers classified into seven groups, and performed ordinal regression analysis.

Results

The mean number of LNs was 41. A higher degree of HIR was significantly associated with male sex, EBV+, non-intestinal histology by Lauren classification, earlier American Joint Committee on Cancer (AJCC) stage, and greater number of LNs (P < 0.001). Female gender, younger age (< 60 years), EBV+, non-intestinal histology, higher HIR grade (G2 and G3), larger tumor size, and deeper invasion depth were significantly related to a higher number of LNs, with an odds ratio greater than 1. In cancer-specific survival analyses, EBV+, younger age, higher HIR grade (G3), and increased number of LNs were independent prognostic factors in addition to AJCC stage.

Conclusions

The HIR was associated with increased number of LNs was a significant favorable prognosticator.

Notes

Acknowledgments

This work was supported by a grant from the National Research Foundation of Korea (NRF-2017R1D1A1B03032449 to KMK).

Supplementary material

10434_2018_6731_MOESM1_ESM.docx (26 kb)
Supplementary material 1 (DOCX 25 kb)
10434_2018_6731_MOESM2_ESM.docx (24 kb)
Supplementary material 2 (DOCX 23 kb)
10434_2018_6731_MOESM3_ESM.tif (1.8 mb)
Supplementary material 3 (TIFF 1877 kb)

References

  1. 1.
    Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306.CrossRefGoogle Scholar
  2. 2.
    Park C, Cho J, Lee J, et al. Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. Oncoimmunology. 2017;6:e1356150.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Hendry S, Salgado R, Gevaert T, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol. 2017;24:235–51.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.CrossRefGoogle Scholar
  5. 5.
    Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69–74.CrossRefGoogle Scholar
  6. 6.
    Naboush A, Roman CA, Shapira I. Immune checkpoint inhibitors in malignancies with mismatch repair deficiency: a review of the state of the current knowledge. J Investig Med. 2017;65:754–8.CrossRefGoogle Scholar
  7. 7.
    Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1:1319–23.CrossRefGoogle Scholar
  8. 8.
    Tashiro H, Brenner MK. Immunotherapy against cancer-related viruses. Cell Res. 2017;27:59–73.CrossRefGoogle Scholar
  9. 9.
    Dieu-Nosjean MC, Goc J, Giraldo NA, Sautes-Fridman C, Fridman WH. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 2014;35:571–80.CrossRefGoogle Scholar
  10. 10.
    Germain C, Gnjatic S, Tamzalit F, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med. 2014;189:832–44.CrossRefGoogle Scholar
  11. 11.
    Messina JL, Fenstermacher DA, Eschrich S, et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep. 2012;2:765.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Buisseret L, Desmedt C, Garaud S, et al. Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. Mod Pathol. 2017;30:1204–12.CrossRefGoogle Scholar
  13. 13.
    Vayrynen JP, Sajanti SA, Klintrup K, et al. Characteristics and significance of colorectal cancer associated lymphoid reaction. Int J Cancer. 2014;134:2126–35.CrossRefGoogle Scholar
  14. 14.
    Song HJ, Srivastava A, Lee J, et al. Host inflammatory response predicts survival of patients with Epstein–Barr virus-associated gastric carcinoma. Gastroenterology. 2010;139:84–92.Google Scholar
  15. 15.
    Sakimura C, Tanaka H, Okuno T, et al. B cells in tertiary lymphoid structures are associated with favorable prognosis in gastric cancer. J Surg Res. 2017;215:74–82.CrossRefGoogle Scholar
  16. 16.
    Nakamura K, Smyth MJ. Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol. 2017;95:325–32.CrossRefGoogle Scholar
  17. 17.
    Deschoolmeester V, Baay M, Van Marck E, et al. Tumor-infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol. 2010;11:19.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    van Duin D, Allore HG, Mohanty S, et al. Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults. J Infect Dis. 2007;195:1590–7.CrossRefGoogle Scholar
  19. 19.
    Haynes L, Eaton SM. The effect of age on the cognate function of CD4+ T cells. Immunol Rev. 2005;205:220–8.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Park ES, Do IG, Park CK, et al. Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection. Clin Cancer Res. 2009;15:291–8.CrossRefGoogle Scholar
  21. 21.
    Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.CrossRefGoogle Scholar
  22. 22.
    Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012;13:722–8.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540–50.CrossRefGoogle Scholar
  24. 24.
    Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Han DS, Suh YS, Kong SH, et al. Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer. J Clin Oncol. 2012;30:3834–40.CrossRefGoogle Scholar
  26. 26.
    Cho J, Kang MS, Kim KM. Epstein–Barr virus-associated gastric carcinoma and specific features of the accompanying immune response. J Gastric Cancer. 2016;16:1–7.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Camargo MC, Kim WH, Chiaravalli AM, et al. Improved survival of gastric cancer with tumour Epstein–Barr virus positivity: an international pooled analysis. Gut. 2014;63:236–43.CrossRefGoogle Scholar
  28. 28.
    Msika S, Benhamiche AM, Jouve JL, Rat P, Faivre J. Prognostic factors after curative resection for gastric cancer: a population-based study. Eur J Cancer Oxford England 1990. 2000;36:390–6.Google Scholar
  29. 29.
    Min BH, Tae CH, Ahn SM, et al. Epstein–Barr virus infection serves as an independent predictor of survival in patients with lymphoepithelioma-like gastric carcinoma. Gastric Cancer. 2016;19:852–9.CrossRefGoogle Scholar
  30. 30.
    Yamashita K, Hosoda K, Ema A, Watanabe M. Lymph node ratio as a novel and simple prognostic factor in advanced gastric cancer. Eur J Surg Oncol. 2016;42:1253–60.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Sun-Ju Byeon
    • 1
  • You Jeong Heo
    • 1
  • Junhun Cho
    • 1
  • Ji Yeong An
    • 2
  • Min Gew Choi
    • 2
  • Jun Ho Lee
    • 2
  • Jae Moon Bae
    • 2
  • Min-Ji Kim
    • 3
  • Insuk Sohn
    • 3
  • Sung Kim
    • 2
  • Kyoung-Mee Kim
    • 1
  • Tae Sung Sohn
    • 2
  1. 1.Department of Pathology and Translational Genomics, Samsung Medical CenterSungkyunkwan UniversitySeoulKorea
  2. 2.Department of Surgery, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulKorea
  3. 3.Statistics and Data Center, Samsung Biomedical Research InstituteSamsung Medical CenterSeoulKorea

Personalised recommendations